ZYUS Life Sciences Corporation
ZLSCF
$0.60
-$0.06-9.09%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -26.86M | -27.12M | -30.36M | -31.46M | -17.87M |
| Total Depreciation and Amortization | 2.19M | 2.23M | 2.15M | 2.30M | 1.55M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | 724.90K |
| Total Other Non-Cash Items | 14.95M | 14.63M | 18.06M | 19.37M | 7.50M |
| Change in Net Operating Assets | 4.28M | -512.80K | -3.98M | -3.60M | -4.55M |
| Cash from Operations | -5.45M | -10.77M | -14.13M | -13.38M | -12.66M |
| Capital Expenditure | -174.40K | -192.40K | -196.90K | -207.20K | -265.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 0.00 | 0.00 | 3.66M | 3.66M | 3.64M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -174.40K | -192.40K | 3.47M | 3.46M | 3.37M |
| Total Debt Issued | 700.00K | 400.00K | 18.79M | 21.24M | 23.58M |
| Total Debt Repaid | -3.36M | -1.31M | -4.39M | -4.11M | -3.93M |
| Issuance of Common Stock | 3.31M | -- | -- | -- | 0.00 |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 476.00K | -679.70K | 10.73M | 12.75M | 14.60M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -5.14M | -11.64M | 60.80K | 2.82M | 5.32M |
